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Background: Despite the high comorbidity of anxiety and depression in people with multiple sclerosis (MS), little is
known about their inter-relationships. Both involve emotional perturbations and the way in which emotions are
processed is likely central to both. The aim of the current study was to explore relationships between the domains
of mood, emotional processing and coping and to analyse how anxiety affects coping, emotional processing,
emotional balance and depression in people with MS.
Methods: A cross-sectional questionnaire study involving 189 people with MS with a confirmed diagnosis of MS
recruited from three French hospitals. Study participants completed a battery of questionnaires encompassing the
following domains: i. anxiety and depression (Hospital Anxiety and Depression Scale (HADS)); ii. emotional
processing (Emotional Processing Scale (EPS-25)); iii. positive and negative emotions (Positive and Negative
Emotionality Scale (EPN-31)); iv. alexithymia (Bermond-Vorst Alexithymia Questionnaire) and v. coping (Coping with
Health Injuries and Problems-Neuro (CHIP-Neuro) questionnaire. Relationships between these domains were
explored using path analysis.
Results: Anxiety was a strong predictor of depression, in both a direct and indirect way, and our model explained
48% of the variance of depression. Gender and functional status (measured by the Expanded Disability Status Scale)
played a modest role. Non-depressed people with MS reported high levels of negative emotions and low levels of
positive emotions. Anxiety also had an indirect impact on depression via one of the subscales of the Emotional
Processing Scale (“Unregulated Emotion”) and via negative emotions (EPN-31).
Conclusions: This research confirms that anxiety is a vulnerability factor for depression via both direct and indirect
pathways. Anxiety symptoms should therefore be assessed systematically and treated in order to lessen the
likelihood of depression symptoms.
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Multiple sclerosis (MS) is an autoimmune degenerative
disease of the central nervous system associated with sig-
nificant behavioural and emotional sequelae [1–3]. People
with MS have to contend on a daily basis with a range of
physical, cognitive and psychological symptoms, such as
walking and mobility limitations, pain, fatigue, depression,
memory and concentration difficulties [4]. MS impacts on
all spheres of people’s lives including employment, rela-
tionships and social life, leisure and activities of daily living* Correspondence: marieclaire.gay@gmail.com
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uncertainty due to the variable nature of the disease
course; for example, risks of relapses, hospital admissions
and of further disability developing [6]. As there is cur-
rently no cure for MS and it is typically diagnosed in the
prime of life, people live with these challenging symptoms
and variable disease course over many years [5].
It is, therefore, not surprising that anxiety disorders
have been reported in the literature as being present in
between 36 – 54% of the MS population with approxi-
mately 30% of people with MS experiencing symptoms
consistent with generalised anxiety disorder [7–9]. More
than half of people with MS experience depression atle is distributed under the terms of the Creative Commons Attribution 4.0
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Alexithymia, a difficulty in identifying and describing
emotions, is also common; affecting up to 42% of people
with MS. [12, 13] Research on coping (the way people
manage their relationships with their environment to ad-
just to their disease) [14] suggests that symptoms are
worsened by an emotion-centred approach [15, 16].
However, despite the high comorbidity of anxiety and
depression in people with MS, little is known about the
relationship between them. Brown et al. [17] showed
that anxiety and depression predict each other with anx-
iety predicting later depression. Gay et al. [18] indicated
that anxiety is a strong predictor of depression and that
its impact on depression is heightened by the presence
of alexithymia and a lack of social support.
Both anxiety and depression involve emotional disrup-
tions or perturbations. Emotions are very rapid adaptive
responses consisting of physiological, cognitive and be-
havioural elements [19]. These are felt by the individual
in terms of positive or negative emotions.
According to Watson and Clark’s model of anxiety and
depression [20, 21], depression is characterised by an ab-
normally high level of negative emotions and an abnor-
mally low level of positive emotions, while anxiety is
linked to a high level of negative emotions but without
perturbations of positive emotions. Emotional balance re-
fers to the respective levels of positive and negative emo-
tions experienced by an individual. There is an emotional
imbalance in anxiety and depression disorders [22, 23].
Emotional perturbations can also occur as processes.
Baker et al. have developed a model of emotional regula-
tion [24, 25] that draws upon Rachman's conceptualisa-
tion of emotional processing [26]. Rachman proposes that
certain behavioural signs (e.g. intrusive and repetitive
emotional memories) indicate that distressing emotional
events have not been properly ‘emotionally processed’ or
‘absorbed’ [26]. Difficulties can occur at different stages of
emotional processing in terms of registration, appraisal,
experience, awareness and expression. Five emotional
dysregulation processes have been identified [25]: “sup-
pression” referring to an excessive control of emotions;
“signs of unprocessed emotion”, reflecting cognitive and
behavioural signs of incomplete processing; “unregulated
emotion”, consisting of an inability to control one's emo-
tions; “avoidance”, referring to the avoidance of negative
emotions and “impoverished emotional experience” con-
sisting of a detached experience of emotions due to poor
emotional insight.
A key issue is how emotional perturbations (imbalances
in positive and negative emotions and emotional process-
ing deficits) lead to depression and whether anxiety exerts
an impact directly on depression in MS or whether it
influences depression via factors related to emotional pro-
cessing. The aim of the current study was to explore therelationship between anxiety and depression and the
relevance of emotional processing, emotional balance, and
coping to depressive symptomatology.
Methods
All the required ethical authorisations were obtained from
the French Ethics Committee (Comité de Protection des
Personnes (CPP)) and all study participants provided
written informed consent.
Participants and procedure
A cross-sectional questionnaire study was undertaken.
Participants were patients recruited from the day care
unit of the neurological departments in three French
university hospitals (CHU Metz, CHI Poissy-Saint
Germain, CHU La Pitié-Salpêtrière) with a neurologist-
confirmed diagnosis of MS (revised McDonald criteria)
[27]. Recruitment took place in 2013.
The research study was described to potential partici-
pants by the neurologist. If they wished to participate, a
psychology Masters student, trained for the study, ob-
tained their written informed consent and then collected
socio-demographic and medical information from them.
Participants completed the battery of self-reported out-
come measures in the day care unit. The trainee was
available to answer questions if required.
Descriptors
Socio-demographic and clinical variables
Socio-demographic variables (age, gender, education level
and marital status) were obtained by the psychology student
and clinical and disease-specific variables (type of MS and
time since diagnosis) were obtained from medical notes.
Physical Disability
The Expanded Disability Status Scale [28] was used as a
measure of physical disability. The Expanded Disability
Status Scale (EDSS) was administered by an experienced
neurologist and provided a measure of functional status.
The EDSS is divided into eight functioning systems
(pyramidal, cerebellar, brainstem, cerebral/mental, bowel
and bladder, visual function, sensory, and other). Impair-
ment in each system is graded separately by means of
neurological examination. EDSS scores range as steps
from 0 – 10 in 0.5 increments. Levels 1.0 – 4.5 refer to
people with a high degree of ambulatory ability and the
subsequent levels 5.0 – 9.5 refer to a loss of ambulatory
ability. The range of main categories include (0) = normal
neurologic exam; to (5) = ambulatory without aid or rest
for 200 m, disability severe enough to impair full daily
activities; to (10) = death due to MS.
Outcomes
All outcomes were self-reported.
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The Hospital Anxiety and Depression Scale (HADS) is a
14-item scale for use as a brief instrument for detecting
the intensity of depression and anxiety in patient popu-
lations [29]. The HADS has few somatic items so is un-
likely to confound depression with physical symptoms such
as pain and fatigue and has been validated for use in the
MS population [30]. Scores for the depression and anxiety
subscales can range from 0 – 21 respectively, with a score
>10 indicating probable anxiety or depression. The French
adaptation of the HADS confirmed Zigmond and Snaith’s
[29] original two factor structure and has been shown to
possess good psychometric properties [31]. Internal reliabil-
ity was 0.79 for the anxiety subscale and from 0.82 for the
depression subscale. The correlation between the two sub-
scales was significant but moderate (r = .47), representing
22% of the common variance [31].
Emotional processing
The Emotional Processing Scale (EPS-25) is a 25-item
self-report questionnaire designed to identify and meas-
ure emotional processing styles and potential deficits in
healthy individuals and those with psychological or
physical disorders [24, 25]. It comprises five subscales,
each with five items that are rated on a 10-point (0–9)
attitudinal scale: suppression (excessive control of emo-
tional experience and expression), signs of unprocessed
emotion (intrusive and persistent emotional experi-
ences), unregulated emotion (inability to control one's
emotions), avoidance (avoidance of negative emotional
triggers), impoverished emotional experience (detached
experience of emotions due to poor emotional insight).
A higher score indicates poorer emotional processing
with a possible mean score range of 0–9. In the original
English language version of the EPS developed in the
UK [25] these five factors explained 59.4% of the total
variance and overall internal reliability (Cronbach's
Alpha) was high (α = 0.92), ranging from 0.70 – 0.80 for
the five respective factors. The EPS-25 has been trans-
lated into numerous languages and norms have been
produced for a wide range of clinical and non-clinical
populations. A French version has been developed (Gay
et al., not yet published). In the French adaptation the
five factors explained 61.5% of the total variance and
overall internal reliability (Cronbach’s Alpha) was 0.91
and ranged from 0.68 – 0.84 for the five respective
subscales. A French sample of healthy adults from the
general population (N = 75) had a mean (SD) total EPS
score of 2.5 (1.04) and mean (SD) scores for the
respective subscales, as follows: Suppression = 3.0
(1.89); Signs of Unprocessed Emotion = 3.3 (1.79);
Unregulated Emotion = 1.9 (1.31); Avoidance = 2.9
(1.36); Impoverished Emotional Experience = 1.4 (1.19).
French data from 349 people with MS showedsignificant differences on every subscale compared to
healthy adults with the exception of the Suppression
subscale. The mean (SD) total EPS score for the MS
sample was 3.2 (1.69) and means (SDs) for the respect-
ive subscales were: Suppression = 3.5 (2.39); Signs of
Unprocessed Emotion = 3.7 (2.80); Unregulated Emo-
tion = 2.6 (1.86); Avoidance = 3.5 (1.90) and Emotional
Experience = 3.5 (1.89).
Emotional balance
The Positive and Negative Emotionality Scale (EPN-31)
[22, 23] measures emotionality; in particular, the self-
reported frequency with which 31 emotional states have
been experienced in the past month. It consists of 31
items and produces three main scores: a positive emo-
tionality score, a negative emotionality and a surprise
emotionality score. The answer format is a 7-point scale,
ranging from 1 “Not experienced at all” to 7 “Experi-
enced this affect several times each day”. For the French
adaptation these three factors explained 58.2% of the
total variance and internal reliability was good with
Cronbach’s Alphas between 0.80 and 0.95 for all main
scores and between 0.72 and 0.90 for the six subscores
(joy, tenderness, anger, fear, sadness, shame) [23]. A ref-
erence population comprising 948 French healthy adults
(mean (SD) age = 41.4 (9.64) years) had a mean (SD)
negative emotion score of 32.0 (14.30) and a mean posi-
tive emotion score of 70.1 (16.00) [23].
Alexithymia
The Bermond-Vorst Alexithymia Questionnaire [32, 33]
(BVAQ) is a 40-item self-report measure which com-
prises two parallel versions, each with 20 items. We have
used the B form. Five factors are assessed: difficulty in
verbalising feelings, difficulty in identifying feelings, lack
of emotional excitability, externally-oriented thinking,
poor fantasy life. Each item is rated on a five-point
Likert-type scale, ranging from 1 (strongly agree) to 5
(strongly disagree), with a maximum score of 100. A
score over 52 is indicative of the presence of alexithymia.
The French version of the BVAQ has demonstrated good
psychometric properties with Cronbach’s Alpha coeffi-
cient 0.83 for a sample of 322 Belgian students [33].
Coping
The Coping with Health Injuries and Problems-Neuro
(CHIP-Neuro) Questionnaire consists of 24 items asses-
sing the coping strategies of people with neurological
conditions [34, 35]. The questionnaire includes six dif-
ferent coping strategies for neurological health problems:
emotional regulation (seven items), seeking well-being
(five items), active distraction (three items), information
seeking (three items), palliative coping (three items) and
cognitive avoidance (three items). Items are rated on a
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lot”, with a possible total score ranging from 0 – 120. A
dominant coping strategy can be identified according to
respondents’ highest subscale score. The CHIP-Neuro
has been validated with a French sample of people with
multiple sclerosis and Parkinson’s disease (N = 307) with
48% of the variance explained by the six factor solution.
The internal reliability was good with Cronbach’s Alphas
ranging between 0.80 and 0.82 for the six subscales.
Statistical analysis
The variables introduced in the analysis were checked
for normality by examining histograms and considering
values for kurtosis and skewness. Descriptive statistics
were used to summarise these data and Pearson’s
Product Moment Correlation Coefficients were used to
explore associations between the various domains of
interest.
Path analysis was used to estimate the strength of the
direct and indirect relationships between the variables of
interest. Chi-squared, the Root Mean Square Error of
Approximation (RMSEA) and the Comparative Fit Index
(CFI) statistics were used as measures of fit.
SPSS Version 21 for Windows was used to undertake
the descriptive and correlational analyses and AMOS
20.0 structural equation modeling software for the path
analyses. We imputed missing data using a multiple im-
putation method based on a Monte-Carlo Markov Chain
algorithm [36]. The chosen algorithm imputes values for
each case by drawing, at random, from the conditional
distribution of the missing values given the observed
values, with the unknown model parameters set equal to
their maximum likelihood estimates.
Results
In total 189 participants completed the questionnaire
battery. The mean age was 47.2 years (SD = 12.50; range
= 18–78). Females (females = 121; males = 68) comprised
approximately two-thirds of the sample reflecting gender
prevalence ratios in the general multiple sclerosis popu-
lation. Just over half the participants were married or in
long term relationships and just over two-thirds had re-
ceived education up to the age of 17 years. In terms of
type of MS, 107 (57%) of the sample had relapsing re-
mitting MS, 54 (29%) secondary progressive MS and 28
(15%) primary progressive MS. The Expanded Disability
Status Scale (EDSS) was used as an index of functional
status and the sample had a mean (SD) EDSS score of
4.7 (2.37) and a mean [(SD) range] disease duration of
15.0 [(9.29) 2–18] years.
Levels of missing total score data for the outcome
measure questionnaires were very low (less than 3%)
with the exception of the EPN-31 scale for which 8% of
total scores were missing.Descriptives for the self-reported outcome variables
for the entire sample are presented in Table 1. Overall
the sample had a self-reported level of depression in
the normal range (HADS depression score M = 8.0,
SD = 4.19). However, 19% of participants scored between
8 and 10 on the HADS depression subscale indicating
possible depression and 28% scored over 10 indicating
probable symptoms of depression. Using a cut-off score
>10 on each respective subscale for probable anxiety
and/or depression, 16/189 (8.5%) participants had both
anxiety and depression; 8/189 (4.2%) had anxiety only;
37/189 (19.6%) had depression only and 128/189 (67.7%)
had neither depression nor anxiety. There was a statisti-
cally significant difference (t(187) = 3.26, p < .001))
between HADS depression scores for females (M = 8.7,
SD = 4.37) and males (M = 6.7, SD = 3.50) with females
tending to score higher than males. Self-reported levels
of anxiety were in the normal range (M = 5.8, SD = 3.78).
However, 17% had scores between 8 and 10 suggesting
possible anxiety and 13% had scores >10 indicating
probable anxiety.
With the exception of the Avoidance subscale, mean
EPS-25 scores were comparable to those found in the
general population [26]. Thirty-six percent of the current
MS sample scored more than one standard deviation
above the mean on the Avoidance subscale. Females
(M = 4.1; SD = 1.95) had significantly higher scores than
males (M = 3.4; SD = 1.98) on the Unregulated Process-
ing subscale, t(187) = 2.35, p = .02.
On the CHIP-Neuro questionnaire mean scores for
the Emotion Regulation and Well-being subscales were
twice as high as those for the other subscales suggesting
these were the most common coping strategies used by
respondents.
The cut-off for clinical alexithymia on the BVAQ is
≥53. The mean (SD) BVAQ total score for the current
MS sample was 55.4 (14.15) with just over half (53%) the
sample scoring at or above this cut-off.
The results showed a perturbation of emotional
balance assessed by the EPN-31, with the sample self-
reporting a much higher level of negative emotions
(M = 51.0; SD = 19.64) and lower level of positive
emotions (M = 47.2; SD = 11.79) compared to a
healthy French adult reference population (N = 948)
[30]. There was a statistically significant difference
(t(187) = 2.28, p = .02) between negative emotion
scores for females (M = 53.4, SD = 20.02) and males
(M = 46.7, SD = 18.31) with females tending to score
higher than males.
The relationships between anxiety, depression, emotions,
emotional processing, and functional status
The relationships between depression and the other var-
iables were explored using Pearson’s Product Moment
Table 1 Descriptive statistics for the self-reported outcomes
Descriptives
Unless otherwise specified [(mean (SD) range)]
Outcome measure Entire sample (N = 189)
Hospital Anxiety and Depression Scale (HADS) (higher scores, more distress)
Depression subscale (HADS-D) 8.0 (4.18) 1–19
Score <8 [N (%)] 100 (52.91%)
Score 8–10 [N (%)] 36 (19.04%)
Score >10 [N (%)] 53 (28.04%)
Anxiety subscale (HADS-A) 5.8 (3.9) 0–18
Score <8 [N (%)] 133 (70.37%)
Score 8–10 [N (%)] 32 (16.93%)
Score >10 [N (%)] 24 (12.70%)
Emotional Processing Scale (EPS-25) (higher scores, poorer emotional processing)
Suppression 4.0 (2.64) 0–9.0
Signs of Unprocessed Emotions 4.1 (2.35) 0–8.4
Unregulated Emotion 2.6 (1.97) 0–8.8
Avoidance 3.9 (1.99) 0–8.2
Impoverished Emotional Experience 2.6 (1.89) 0–8.2
Total EPS Score 4.3 (2.12) 0–9.0
Bermond-Vorst Alexithymia Questionnaire (BVAQ) (higher scores, greater levels of alexithymia)
Difficulty in verbalising feelings 11.8 (4.09) 4–20
Poor fantasy life 11.2 (4.33) 4–20
Difficulty identifying feelings 10.9 (4.04) 4–20
Lack of emotional excitability 10.8 (4.31) 4–20
Externally-oriented thinking 10.7 (4.45) 4–20
Total BVAQ Score 55.4 (14.15) 20–95
Coping with Health Injuries and Problems – Neuro (CHIP-Neuro) (higher scores, greater use of coping style)
Emotional regulation 22.0 (6.65) 7–35
Seeking Well-being 19.2 (3.18) 9–25
Active Distraction 9.1 (3.16) 3–15
Information Seeking 9.8 (4.00) 3–15
Palliative Coping 7.9 (2.99) 3–15
Cognitive Avoidance 8.3 (2.93) 3–15
Positive and Negative Emotionality (EPN-31) (higher scores, greater emotionality)
Positive 47.2 (11.78) 10–70
Negative 51.0 (19.63) 18–111
Surprise 8.3 (3.98) 3–19
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anxiety scores were moderately positively correlated with
HADS depression scores (rp = .41, p < .001). HADS anx-
iety scores were moderately positively correlated with
total EPS scores (rp = .40, p < .001) and moderately posi-
tively correlated with negative emotion scores on the
EPN-31 (rp = .35, p < .001). HADS anxiety scores were
moderately negatively correlated with positive emotion
scores (rp = −.64, p < .001). Regarding coping, a moderatenegative correlation was found with the active distrac-
tion subscale score of the CHIP-Neuro (rp = -.49,
p < .001) as well as a moderate positive association with
emotional regulation-based coping (rp = .36, p < .001).
Scores on the HADS depression subscale correlated
positively and strongly with negative emotion scores on
the EPN-31 (rp = .60, p < .001) and with EPS total scores
(rp = .57, p < .001) and more specifically with the Signs
of Unprocessed Emotions (rp = .55, p < .001) and
Table 2 Correlations between HADS depression scores and EDSS, HADS anxiety, EPN-31 and EPS scores (N = 189)
EDSS HADS
Anxiety
EPN-31
Negative
EPN-31
Positive
EPS
Suppression
EPS
Unprocessed
EPS
Unregulated
EPS
Avoidance
EPS
Impoverished
EPS
Total
HADS
depression
-.19* .42*** .62*** -.07 ns .38*** .56*** .53*** .39*** .39** .58***
* p <.05; ** p <.01; *** p <.001; ns Not significant
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HADS depression scores correlated positively and mod-
erately with scores on the Emotional Regulation sub-
scale of the CHIP-Neuro (rp = .45, p < .001) and weakly
and negatively with EDSS scores (rp = −.18, p < .05).
There were no statistically significant differences
between depressed and non-depressed participants in
terms of alexithymia scores, F(2,186) = 1.36, p = .26, nor
between anxious and non-anxious participants,
F(2,186) = 1.99), p = .14.The study of the direct and indirect effects of the
variables using path analysis model
The path analysis aimed to explore the direct and indirect
effects of anxiety on depression. Functional status was
retained in the model to control for MS severity. A covari-
ance relationship between functional status and anxiety
was introduced into the model to take into account the
existence of a link between these variables. Variables were
introduced into the model if they were significantly corre-
lated with anxiety and/or depression (see Tables 2, 3, 4).
Alexithymia was therefore not included in the model.
Among the variables representing emotional processing,
only “Unregulated Emotion” was selected because its cor-
relation was one of the highest with depression. Despite a
high correlation with depression, “Signs of Unprocessed
Emotion” was not introduced into the model because its
shared variance with “Unregulated Emotion” led to a sup-
pressing effect on this variable. As no specific hypothesis
was available on the direction of a causal link between
“negative emotions” and “Unregulated Emotion”, their re-
lationship was estimated as a covariance.
The path analysis model included both direct and in-
direct effects on the dependent variable “depression”.
One variable (functional status) had only direct effects.
One (anxiety) had direct and indirect effects mediated
by “Unregulated Emotion” and by “negative emotions”.
The model consists of 13 parameters. The sample size
(N = 189) seems sufficient for a reliable estimation of
these parameters at .80 power according to the R2 valueTable 3 Correlations between HADS depression scores and BVAQ sc
BVAQ
Verbalisation
BVAQ
Fantasy
BV
Ide
HADS depression .03 ns .09 ns -.01
* p <.05; ** p <.01; *** p <.001; ns Not significant(.46) and the direct and indirect effect sizes following re-
sults from Thoemmes et al. [37].
The non-significant Chi-squared test statistic indicated
acceptable goodness-of-fit of the model (χ2 (2) = 4.12,
p = .13). The Root Mean Square Error of Approximation
(RMSEA) was 0.075 indicating an acceptable fit (RMSEA
values < 0.08 indicate an acceptable fit), the Comparative
Fit Index (CFI) was 0.98 indicating an acceptable fit
(values >0.90 indicate an acceptable fit) [38]. Figure 1
presents the standardised values of the regression coeffi-
cients. All the values are significant at p = .001.
The model explained almost half of the variance of de-
pression (R2 = .46). The direct effect of anxiety on de-
pression is estimated at .24, the indirect effects (negative
emotions, Unregulated Emotion) at .22.
Discussion
In this research our aim was to explore the relationship
between anxiety and depression in a sample of people with
MS and the relevance of emotional processing to depressive
symptomatology. We also examined the respective contri-
butions of several sociodemographic, clinical and psycho-
logical factors to depressive symptomatology.
In line with the literature [10, 11], the results con-
firmed that depression is prevalent in people with MS.
HADS anxiety scores >10 were obtained by 8% of the
sample which is lower than is commonly reported in the
MS literature [7–9] though 17% had scores suggesting
possible anxiety.
The results also indicated that people with MS had
perturbations in their emotional balance, according to
Watson and Clark’s model [20, 21]; they reported
fewer positive emotions than the general population
and more negative ones. Their mean scores were
similar to those observed in people with anxiety and
depressive disorders [22] which is in line with previ-
ous research in MS [15].
However, in the current study people with MS with
probable anxiety disorder also showed perturbation of
their positive emotions. Another difference from
Watson and Clark’s model is that even non-depressedores (N = 189)
AQ
ntification
BVAQ
Excitability
BVAQ
Externality
BVAQ
Total
ns .09 ns .04 ns .07 ns
Table 4 Correlations between HADS anxiety scores, EPN-31 and EPS scores (N = 189)
EPN-31
Negative
EPN-31
Positive
EPS
Suppression
EPS
Unprocessed
EPS
Unregulated
EPS
Avoidance
EPS
Impoverished
EPS
Total
HADS
anxiety
.36*** -.64*** .36*** .34*** .35*** .31*** .34*** .58***
* p <.05; ** p <.01; *** p <.001; ns Not significant
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tions and low levels of positive emotions. This result
suggests that experiencing negative emotions is not
sufficient to develop depression or to feel depressed.
Negative emotions were nevertheless strongly impli-
cated in depression, through dysfunctional emotional
processing and anxiety.
Anxiety was a strong predictor of depression via both
direct and indirect pathways. Indirect pathways were via
one of the subscales of the Emotional Processing Scale,
“Unregulated Emotion” and through negative emotions
(EPN-31).
Functional status had an independent impact on depres-
sion. This impact was low, which is in line with the litera-
ture [18]. Anxiety and functional status were independent.
The separation between anxiety and functional status
indicated that functional status did not impact on anxiety.
It may be that individuals’ illness representations [39] and
the anticipation of possible future consequences of MS [6]
may provoke anxiety above and beyond that arising from
current symptoms and functional status. In turn, this
anxiety may inhibit healthy emotional processing.
Coping strategies did not appear to mediate the rela-
tionship between anxiety and emotional processing nor
that between anxiety and depression. While alexithymia
did not contribute to the final model we cannot exclude
the possibility that this was due to the specific scale we
used. Future research should also include other mea-
sures of alexithymia such as the Toronto Alexithymia
Scale (TAS-20) [33].
In conclusion, our model explained 46% of the variance
of depression. It is consistent with Watson and Clark’s
model of depression [21]; having high levels of negative
emotions and few positive ones is a feature of depression.
Depressed people with MS had such a configuration of
emotions. The unpredictable and variable nature of MS
may explain how anxiety can lead to perturbations in
emotional balance.
Anxiety is a vulnerability factor for depression
since it directly and indirectly induces negative emo-
tions which can lead to depressive symptoms. A
similar pattern of relationships between anxiety and
depression has been demonstrated by researchers
using other questionnaires specifically assessing anx-
iety (the State and Trait Anxiety Inventory- STAI
[40]) and depression (the ZUNG Self-Rating Depres-
sion Scale [41]).Study limitations
It could be argued that it might have been better to assess
depression and anxiety using two separate scales. However,
it is challenging to assess depression in people with MS
since symptoms of MS overlap with depression (asthenia, fa-
tigue, loss of energy, psychomotor impairment, appetite dis-
orders, sleep disorders, sexual disorders, and cognitive
disorders) and an advantage of the HADS depression sub-
scale is that it contains few somatic items, has been validated
in French and has been widely used with people with MS.
The study is based on self-reported measures and we
know that people with depression tend to report more
negatively in retrospective recall. Additionally, it would
have been good to collect information on disease modi-
fying treatments and to have included fatigue [17] and
social support in the model.
There are inherent and well-recognised limitations in
drawing conclusions about directionality in cross-
sectional research of this kind. Prospectively designed
studies would overcome such limitations.
Despite these acknowledged limitations, our research
has strengths in showing how anxiety may affect depres-
sion in people with MS. The model we have proposed
explained just under half the variance of depression and
so clearly there are a range of other potential contribu-
tors (such as neurological dysfunction). Nevertheless,
our findings suggest that anxiety plays an important role
in the presence of depression.
Conclusion
This research confirmed that in the current sample of
people with MS anxiety was a strong predictor of depres-
sion via both direct and indirect pathways. The model ob-
tained suggested that anxiety may affect depression
through unregulated emotion and negative emotions and
highlights an important potential role for early intervention.
We suggest several possible treatment approaches could be
applied to target anxiety. Information provision for people
with MS seems to increase disease-related knowledge, with
less clear results on decision making and quality of life [42].
Cognitive Behavioural Therapy (CBT) has been shown to
be effective for anxiety disorders in the general population
[43] and should be considered for those with MS with signs
of anxiety or anxiety disorders. Interventions should
address both individual and social factors that support
resilience such as promoting positive thinking and plan-
ning and engagement in meaningful activities. Positive
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Fig. 1 Path analysis model (N = 189). Standardised values, all coefficients presented are significant at p < .001)
Gay et al. BMC Neurology  (2017) 17:43 Page 9 of 10psychological approaches that focus on eliciting positive
emotions may provide a means of reducing or even
neutralising the impact of aversive events on emotional
experiences [44–46]. Emotion-focused or experiential
therapies may be particularly helpful for people with poor
awareness of their emotions and psychological functioning
[47, 48]. Recognising the limits of the current research,
there is a need for a more complete consideration of
demographic, disease specific and psychosocial factors
involved in the development of depression and of
their respective contributions. National MS registers
are ideally placed for the longitudinal exploration of
these more complex path models [7].
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